The global kidney cancer drugs market size is expected to be valued at USD 8.6 billion by 2026 with registering a CAGR of 7.2% during the forecast period 2019 to 2026. Market growth is largely driven by factors such as availability of novel drugs and presence of a strong pipeline. Growth can also be attributed to rise in incidence of renal cancer due to growing geriatric population and changes in lifestyle such as increased smoking and intake of alcohol.
Further Key Findings From the Report Suggest:
The report analyzes and forecasts the kidney cancer drugs market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global kidney cancer drugs market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the kidney cancer drugs market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of kidney cancer drugs market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Segmentation:
Therapeutic Class Outlook (Revenue, USD Million, 2019 - 2026)
Targeted Therapy
Immunotherapy
Pharmacologic Class Outlook (Revenue, USD Million, 2019 - 2026)
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (IL-2)
Country Outlook (Revenue, USD Million, 2019 - 2026)
U.S.
U.K.
France
Germany
Italy
Spain
Japan
Reasons to Purchase this Report:
- Estimates 2019-2026 kidney cancer drugs market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 Assumptions
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Kidney Cancer Drugs Market
2.2 Comparative Analysis: Global Kidney Cancer Drugs Market, By Geography, 2018 and 2026 (Value %)
Chapter 3 Global Kidney Cancer Drugs Market Overview
3.1 Market Dynamics and Overview
3.2 Market Drivers
3.2.1 Rising Incidence of Kidney Cancer Expected to Boost Market Growth
3.2.2 Increasing Geriatric Population Likely to Fuel the Growth of Kidney Cancer Drugs Market
3.2.2.1.1 Global Percentage Change in the World’s Population by Age: 2010-2050
3.2.3 Approval of Novel Molecules is Expected to Drive Market Growth
3.3 Market Restraints
3.3.1 High Prices of Branded Cancer Drugs might Impede the Growth of the Market
3.3.2 Increasing Preference for Generic Drug Variants might Negatively Influence the Market Growth
3.4 Market Opportunities
3.4.1 Focusing on Emerging Markets
3.5 Event Impact Analysis
3.6 Regulatory Framework
3.7 Market Attractiveness Analysis: Global Kidney Cancer Drugs Market, by Geography
3.8 Market Share Analysis: Global Kidney Cancer Drugs Market, by Key Players, 2018 (Value %)
Chapter 4 Global Kidney Cancer Drugs Market, by Major Branded Drugs
4.1 Overview
4.1.1 Global Kidney Cancer Drugs Market Revenue, by Major Branded Drugs, 2016 – 2026 (USD Million)
4.2 Sutent (Sunitinib)
4.2.1 Global Sutent (Sunitinib) Market Revenue, 2016 – 2026 (USD Million)
4.3 Nexavar (Sorafenib)
4.3.1 Global Nexavar (Sorafenib) Market Revenue, 2016 – 2026 (USD Million)
4.4 Afinitor (Everolimus)
4.4.1 Global Afinitor (Everolimus) Market Revenue, 2016 – 2026 (USD Million)
4.5 Votrient (Pazopanib)
4.5.1 Global Votrient (Pazopanib) Market Revenue, 2016 – 2026 (USD Million)
4.6 Inlyta (Axitinib)
4.6.1 Global Inlyta (Axitinib) Market Revenue, 2016 – 2026 (USD Million)
4.7 Avastin (Bevacizumab)
4.7.1 Global Avastin (Bevacizumab) Market Revenue, 2016 – 2026 (USD Million)
4.8 Torisel (Temsirolimus)
4.8.1 Global Torisel (Temsirolimus) Market Revenue, 2016 – 2026 (USD Million)
4.9 Proleukin (Aldesleukin)
4.9.1 Global Proleukin (Aldesleukin) Market Revenue, 2016 – 2026 (USD Million)
Chapter 5 Global Kidney Cancer Drugs Market, Pipeline Analysis
5.1 Overview
5.1.1 Global Kidney Cancer Drugs Market Revenue, by Pipeline Drugs, 2015 – 2026 (USD Million)
5.2 Opdivo (Nivolumab) (Bristol-Myers Squibb)
5.2.1 Global Opdivo Market Revenue, 2015 – 2026 (USD Million)
5.3 Keytruda (Anti PD 1) (Pembrolizumab) (Merck & Co., Inc.)
5.3.1 Global Keytruda Market Revenue, 2015 – 2026 (USD Million)
5.4 Cabozantinib (XL184) (Exelixis, Inc.)
5.4.1 Global Cabozantinib Market Revenue, 2017 – 2026 (USD Million)
5.5 AGS-003 (Argus Therapeutics, Inc.)
5.5.1 Global AGS-003 Market Revenue, 2017 – 2026 (USD Million)
5.6 Dovitinib (TK1258) [Novartis AG]
5.6.1 Global Dovitinib Market Revenue, 2018 – 2026 (USD Million)
Chapter 6 Global Kidney Cancer Drugs Market, by Geography
6.1 Overview
6.1.1 Global Kidney Cancer Drugs Market Revenue, by Geography, 2016 – 2026 (USD Million)
6.2 North America
6.2.1 North America Kidney Cancer Drugs Market Revenue, 2016–2026 (USD Million)
6.3 Europe
6.3.1 Europe Kidney Cancer Drugs Market Revenue, 2016 - 2026 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Kidney Cancer Drugs Market Revenue, 2016 - 2026 (USD Million)
6.5 Rest of the World (RoW)
6.5.1 Rest of the World Kidney Cancer Drugs Market Revenue, 2016 - 2026 (USD Million)
Chapter 7 Recommendations
Chapter 8 Company Profiles
8.1 Bayer AG
8.1.1 Company Overview
8.1.2 Financial Overview
8.1.3 Product Portfolio
8.1.4 Business Strategy
8.1.5 Recent Developments
8.2 F. Hoffmann-La Roche, Ltd.
8.2.1 Company Overview
8.2.2 Financial Overview
8.2.3 Product Portfolio
8.2.4 Business Strategy
8.2.5 Recent Developments
8.3 GlaxoSmithKline, plc
8.3.1 Company Overview
8.3.2 Financial Overview
8.3.3 Product Portfolio
8.3.4 Business Strategy
8.3.5 Recent Developments
8.4 Novartis AG
8.4.1 Company Overview
8.4.2 Financial Overview
8.4.3 Product Portfolio
8.4.4 Business Strategy
8.4.5 Recent Developments
8.5 Pfizer, Inc.
8.5.1 Company Overview
8.5.2 Financial Overview
8.5.3 Product Portfolio
8.5.4 Business Strategy
8.5.5 Recent Developments